Alnylam Pharmaceuticals (ALNY) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.75. This compares to loss of $1.40 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 78.67%. A quarter ago, it was expected that this RNA interference drug developer would post a loss of $1.20 per share when it actually produced a loss of $1.10, delivering a surprise of 8.33%.Over the last four qua ...